Parabilis Medicines, Inc. (PBLS)
Market Closed
15 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
25. 18
-0.71
-2.7424%
$
3.2B Market Cap
- P/E Ratio
- Div Yield
954,610 Volume
- Eps
$ 25.89
Previous Close 
Want to track PBLS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform
Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway into 2030 to support clinical trials, platform expansion, and reduce financing risk. Early zolucatetide data in desmoid tumors show 100% tumor reduction and 74% objective response, with a favorable safety profile versus competitors.
Seekingalpha | 2 months ago
2026 © Marketlog. All Rights Reserved.
